Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
NCT02551159
Completed
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
09/16/2021
Locations: Research Site, Aurora, Colorado +196 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00381706
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one chemotherapy drug (combination chemotherapy) together with cetuximab may kill more tumor cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/02/2021
Locations: Norwalk Hospital, Norwalk, Connecticut +226 locations
Conditions: Esophageal Cancer
Register for Updates
Cisplatin + RT for Triple Negative Breast Cancer
NCT01674842
Completed
This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy. Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2021
Locations: Massachusetts General Hospital, Boston, Massachusetts +4 locations
Conditions: Breast Cancer
Register for Updates
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
NCT02508389
Completed
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2021
Locations: University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix, Arizona +63 locations
Conditions: Radiation Induced Oral Mucositis
Register for Updates
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
NCT03349710
Completed
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2021
Locations: Pinnacle Research Group, Llc, Anniston, Alabama +54 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
NCT02631590
Completed
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
Register for Updates
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
NCT02314117
Completed
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2021
Locations: Highlands Oncology Group, Fayetteville, Arkansas +134 locations
Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Register for Updates
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
NCT02985658
No Longer Available
This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/14/2021
Locations: Seattle Cancer Care Allliance, Seattle, Washington
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Register for Updates
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
NCT00053352
Completed
This phase III trial is studying surgery followed by combination chemotherapy to see how well it works in treating children with germ cell tumors that are not located in the head. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill any remaining tumor cells following surgery. It is not yet known whether combination chemotherapy is effective in decreasing the recurrence o... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/09/2021
Locations: University of Alabama at Birmingham, Birmingham, Alabama +125 locations
Conditions: Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIC Ovarian Germ Cell Tumor, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma
Register for Updates
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531
Completed
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2021
Locations: Stanford Cancer Institute; Hematology, Palo Alto, California +29 locations
Conditions: Solid Tumor
Register for Updates
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
NCT00700336
Completed
The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be determined based on DLTs occurring during the first tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2021
Locations: Mayo Clinic, Scottsdale, Arizona +11 locations
Conditions: Malignant Pleural Mesothelioma, Solid Tumors
Register for Updates
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
NCT02585973
Completed
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2021
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Carcinoma, Squamous Cell of Head and Neck
Register for Updates